Wilmot fellows are off to ASH! (Featuring attending & ALL expert Kristen O’Dwyer). Catch Jozal Moore and Bill Archibald’s posters on MDS and targeting the BMME, & CLL and BCL2i vs BTKi therapy tomorrow evening! Wilmot Cancer Institute ASH instagr.am/p/Cl9zN_fuXGI/

💜 Congratulations Women in Lymphoma - [email protected] 2023 Steering Committee Chair Carla Casulo, MD urmc.rochester.edu/people/2813425… 👏And many thanks 2022 Chair Ann LaCasce, MD for a year packed with growth, accomplishments, advocacy, education & successes #womeninlymphoma #lymphoma Lymphoma Australia URMC Department of Medicine

Thrilled to see our program director and lymphoma specialist Carla Casulo, MD featured in this new UR Medicine ad! So many of us came to fellowship and are staying on as attendings because advances DO happen at Wilmot Cancer Institute ❤️.

Now on the #ACGME Blog! Read our interview with 2023 Parker J. Palmer Courage to Teach Awardee Dr. Alec O’Connor of @URMC_Med URMC Department of Medicine URMC Hospital Medicine Division URMC Internal Medicine Residency URochester SMD. #ACGME2023 #MeaningInMedicine #MedEd acgme.org/newsroom/blog/… via @ACGME

Excited to learn alongside these superstars!

Incredibly proud to see this URMC Internal Medicine Residency abstract by Matt Haley and senior authored by former PD Alex O’Connor on resident and attending perspectives on the physical exam during COVID as a finalist for the Hamolsky Award #SGIM23

A very special moment in lymphoma nerd-dom!! Hearing Bruce Cheson talk, in Lugano, about the history & development of staging and response assessment - the Lugano classification! #17ICML International Conference on Malignant Lymphoma #lymphomaniac #lymsm

Incredible to have such an all-star cast of Women in Lymphoma - [email protected] all together celebrating progress & calling for change Career development, from 3 legends of lymphoma: onlinelibrary.wiley.com/doi/10.1002/ho… Reminding the obvious: onlinelibrary.wiley.com/doi/10.1002/ho… #17ICML International Conference on Malignant Lymphoma

I am incredibly proud to be part of this team. The majority of our cancer patients receive treatment in community settings. At Webster Wilmot Cancer Institute, we are dedicated to providing the finest care, close to home. Moreover, we are actively expanding the availability of clinical

Really proud of this one! Thank you so much for sharing, Christopher Steer !

Found some fellow med-ed nerds at the ASH #ASHMEI! 🤓Great week of education and collaboration. Ready to get to work back home at Wilmot Cancer Institute with our fantastic URMC Internal Medicine Residency residents rotating on our malignant heme service!

Recommending Treatment for Patients With Relapsed DLBCL After CAR T-Cell Therapy : collaboration with Danielle Wallace in The ASCO Post dailynews.ascopubs.org/do/recommendin…

Upstate NY Cancer Symposium Day 2: - Hodgkin’s lymphoma w/ Alex Niu - Non-Hodgkin’s lymphoma w/ Danielle Wallace - CLL w/ Matthew Cortese, MD, MPH Roswell Park Wilmot Cancer Institute #lymsm #HemeTwitter

Proud of this paper with my fantastic mentor Carla Casulo, MD and geriatric oncology expert @MelissaLoh21 👵🚗👴🧬

Amazing collaborations in this successful National Cancer Institute study led by Dr. Herrera. SWOG Cancer Research Network ECOG-ACRIN Cancer Research Group Children’s Oncology Group CCTG Alliance for Clinical Trials in Oncology Inclusive study enrolling pts aged 12+ with remarkable efficacy across all analyzed subgroups. Best-ever reported US results. nejm.org/doi/full/10.10…

How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma ow.ly/GCWG50UGYSl #HowITreat #lymphoidneoplasia

Wilmot Cancer Institute is officially a National Cancer Institute-Designated Cancer Center! This puts us in the nation’s top 4% of cancer centers. #WeareNCIDesignated National Cancer Institute

Sun Sets on R-Gem/Ox as Bispecific Antibodies Rise: Our thoughts on the SUNMO Trial. These results support the use of mosun/pola in patients ineligible or post CAR-T, and mosun/pola should replace R-Gem/Ox in future trials. Journal of Clinical Oncology Wilmot Cancer Institute ascopubs.org/doi/10.1200/JC…